Voyager Therapeutics, Inc.
General ticker "VYGR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $242.7M (TTM average)
Voyager Therapeutics, Inc. follows the US Stock Market performance with the rate: 36.1%.
Estimated limits based on current volatility of 3.4%: low 3.82$, high 4.08$
Factors to consider:
- Total employees count: 172 (+6.2%) as of 2024
- Top business risk factors: Lack of profitability, Market competition, Regulatory and compliance, Labor/talent shortage/retention, Manufacturing risks
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.71$, 8.24$]
- 2025-12-31 to 2026-12-31 estimated range: [3.51$, 7.80$]
Financial Metrics affecting the VYGR estimates:
- Positive: with PPE of -5.1 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -4.63 <= 0.04
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Inventory ratio change, % of -8.73 <= -0.76
- Negative: negative Industry operating cash flow (median)
Short-term VYGR quotes
Long-term VYGR plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $40.91MM | $250.01MM | $80.00MM |
| Operating Expenses | $91.74MM | $127.99MM | $163.29MM |
| Operating Income | $-50.84MM | $122.01MM | $-83.29MM |
| Non-Operating Income | $4.45MM | $11.72MM | $18.95MM |
| R&D Expense | $60.76MM | $92.17MM | $127.37MM |
| Income(Loss) | $-46.39MM | $133.74MM | $-64.34MM |
| Taxes | $0.02MM | $1.41MM | $0.67MM |
| Profit(Loss)* | $-46.41MM | $132.33MM | $-65.00MM |
| Stockholders Equity | $59.02MM | $236.32MM | $299.76MM |
| Assets | $159.36MM | $351.28MM | $393.05MM |
| Operating Cash Flow | $-12.51MM | $77.92MM | $-15.31MM |
| Capital expenditure | $2.49MM | $3.26MM | $3.52MM |
| Investing Cash Flow | $-7.34MM | $-141.64MM | $-94.86MM |
| Financing Cash Flow | $1.11MM | $33.65MM | $114.02MM |
| Earnings Per Share** | $-1.21 | $3.08 | $-1.13 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.